FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207915> ?p ?o ?g. }

• W4387207915 endingPage "S6" @default.
• W4387207915 startingPage "S5" @default.
• W4387207915 abstract "Combined Radiation and Endocrine Therapy (RT+ET) and ET Monotherapy are acceptable adjuvant strategies based on randomized trial data. Less is known about RT Monotherapy as a form of treatment de-escalation. Radiation delivery has become safer and more convenient. This study compares long-term outcomes in patients who opted for RT-Monotherapy versus combined RT+ET.This retrospective study included female patients from Swedish Cancer Institute breast cancer registry (Seattle, WA), aged ≥70 years with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) T1N0 breast cancer treated with BCS between 1995 and 2015. Patients with positive surgical margins, multifocality, histologic grade 3 and LVI were excluded. Patients were classified into 4 groups: (1) RT+ET (reference); (2) RT Monotherapy; (3) ET Monotherapy; and (4) neither RT nor ET (NT). Choice of therapy was determined by the treating physician and the patient. The primary endpoints were local recurrence (LR), distant metastasis (DM), disease specific survival (DSS), overall survival (OS), and second breast cancer events (SBCEs). Competing risk models were used to estimate cumulative incidence at varying lengths of follow-up and sub distribution hazard ratios (HR) between treatment groups. Significance was set at P ≤ .05.We analyzed 496 patients with a median age of 76 years and median follow-up of 9.6 years. 62% (N = 307) of patients received combined RT+ET, 30% (N = 148) RT Monotherapy, 4% (N = 20) ET alone and 4% (N = 21) no therapy, NT group. Only the RT monotherapy and combined RT+ET groups were large enough for a meaningful statistical analysis. RT monotherapy conferred non-inferior disease control compared to combined RT+ET. Recurrence events were extremely low. Incidence of SBCEs was not significantly different between treatments.For this favorable patient population, RT monotherapy was associated with equivalent long-term outcomes compared to combined RT+ET therapy. Recurrence rates stayed extremely low with long-term FU. RT monotherapy may be a reasonable de-escalation option for this older low risk patient population. Further prospective trials are needed to help refine treatment strategies that allow for more choices in treatment de-escalation." @default.
• W4387207915 created "2023-09-30" @default.
• W4387207915 creator A5004147969 @default.
• W4387207915 creator A5048468690 @default.
• W4387207915 creator A5077375752 @default.
• W4387207915 date "2023-10-01" @default.
• W4387207915 modified "2023-10-17" @default.
• W4387207915 title "Long Term Outcomes of Radiation (RT)-Monotherapy vs. Combined RT + Endocrine Therapy (RT+ET) in Low-Risk Early-Stage Breast Cancer Patients 70 Years or Older after Breast-Conserving Surgery (BCS)" @default.
• W4387207915 doi "https://doi.org/10.1016/j.ijrobp.2023.06.212" @default.
• W4387207915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784514" @default.
• W4387207915 hasPublicationYear "2023" @default.
• W4387207915 type Work @default.
• W4387207915 citedByCount "0" @default.
• W4387207915 crossrefType "journal-article" @default.
• W4387207915 hasAuthorship W4387207915A5004147969 @default.
• W4387207915 hasAuthorship W4387207915A5048468690 @default.
• W4387207915 hasAuthorship W4387207915A5077375752 @default.
• W4387207915 hasConcept C121608353 @default.
• W4387207915 hasConcept C126322002 @default.
• W4387207915 hasConcept C141071460 @default.
• W4387207915 hasConcept C143998085 @default.
• W4387207915 hasConcept C207103383 @default.
• W4387207915 hasConcept C2777757722 @default.
• W4387207915 hasConcept C2781467025 @default.
• W4387207915 hasConcept C29456083 @default.
• W4387207915 hasConcept C44249647 @default.
• W4387207915 hasConcept C509974204 @default.
• W4387207915 hasConcept C530470458 @default.
• W4387207915 hasConcept C71924100 @default.
• W4387207915 hasConcept C72563966 @default.
• W4387207915 hasConcept C88879693 @default.
• W4387207915 hasConceptScore W4387207915C121608353 @default.
• W4387207915 hasConceptScore W4387207915C126322002 @default.
• W4387207915 hasConceptScore W4387207915C141071460 @default.
• W4387207915 hasConceptScore W4387207915C143998085 @default.
• W4387207915 hasConceptScore W4387207915C207103383 @default.
• W4387207915 hasConceptScore W4387207915C2777757722 @default.
• W4387207915 hasConceptScore W4387207915C2781467025 @default.
• W4387207915 hasConceptScore W4387207915C29456083 @default.
• W4387207915 hasConceptScore W4387207915C44249647 @default.
• W4387207915 hasConceptScore W4387207915C509974204 @default.
• W4387207915 hasConceptScore W4387207915C530470458 @default.
• W4387207915 hasConceptScore W4387207915C71924100 @default.
• W4387207915 hasConceptScore W4387207915C72563966 @default.
• W4387207915 hasConceptScore W4387207915C88879693 @default.
• W4387207915 hasIssue "2" @default.
• W4387207915 hasLocation W43872079151 @default.
• W4387207915 hasLocation W43872079152 @default.
• W4387207915 hasOpenAccess W4387207915 @default.
• W4387207915 hasPrimaryLocation W43872079151 @default.
• W4387207915 hasRelatedWork W1981700235 @default.
• W4387207915 hasRelatedWork W2060905781 @default.
• W4387207915 hasRelatedWork W2100071372 @default.
• W4387207915 hasRelatedWork W2106734666 @default.
• W4387207915 hasRelatedWork W2126696112 @default.
• W4387207915 hasRelatedWork W2158615473 @default.
• W4387207915 hasRelatedWork W2224319365 @default.
• W4387207915 hasRelatedWork W3029766897 @default.
• W4387207915 hasRelatedWork W3032465624 @default.
• W4387207915 hasRelatedWork W4210934033 @default.
• W4387207915 hasVolume "117" @default.
• W4387207915 isParatext "false" @default.
• W4387207915 isRetracted "false" @default.
• W4387207915 workType "article" @default.